Standigm to showcase AI-powered drug discovery technology at conference
CAMBRIDGE, England, October 18, 2022 /PRNewswire/ — Bannerworkflow AI-driven drug discovery company, announced today that it will be represented at the 28the annual BIO-Europe from October 24 to 26, 2022 in Leipzig – Germany. After being delivered digitally for the past two years, the event is expected to bring together more than 4,000 executives from biotech, pharmaceutical and financial companies for more than 27,000 one-on-one meetings.
The Standigm Business Development (BD) team and members of Standigm UK, including CBOs Charles Foster will attend, presenting the company profile, AI technologies and AI-powered pipelines.
“We are excited to provide an inside look at Standigm at the upcoming BIO-Europe Conference and look forward to having meaningful discussions with partners,” he said. jinhan kim, CEO and co-founder of Standigm. “This is a great opportunity to collaborate with other pharmaceutical and biotech companies to further advance potential solutions for some of the world’s most prevalent diseases.”
Standigm develops world-class drug compounds in an average of seven months, with an AI-driven full molecular design workflow that covers the entire drug discovery process. End-to-end AI platforms allow rapid exploration of hypotheses. The company’s machine learning model achieves high prediction accuracy and its AI technology achieves maximum return on investment.
BIO-Europe is the place to meet the world under one roof and discover the latest innovations that will advance the medicines of tomorrow. EBD Group is committed to providing a forum for the global biopharmaceutical community to come together, which is why this year’s event will also feature three days of digital partnership in the week after the live event.
Follow Standigm on Twitter at @standigm Y LinkedIn.
ABOUT THE STANDARD
Standigm is a workflow AI-powered drug discovery company. The company has a global presence, with offices in the UK, US and Korea. Standigm has proprietary AI platforms that range from novel target identification to compound design, to generating commercially valuable drug blueprints. Founded in 2015 in Seoul, South Korea, Standigm has established an early-stage drug discovery workflow AI to generate multiple first-in-class compounds in an average of seven months. In the pursuit of full-stack AI-driven industrialized drug discovery, Standigm has achieved molecular design workflow automation, and the automation effort has expanded to the entire drug discovery process based on Standigm AI platforms, including Standigm ASK™ for new targets. discovery and Standigm BEST™ for the generation of new compounds. Learn more at http://www.standigm.com.
ABOUT BIO-EUROPE
Over the years, BIO-Europe has become of Europe logo partnership event. Its international reach makes it a unique offering and a gateway to the global life sciences community. The event will cater to the needs of the entire value chain, innovative and start-up educational programs, industry trends and KOL perspectives, company presentations, professional partner meetings, as well as extensive fortuitous creation opportunities. Networking are part of ROI’s proven feature set. BIO-Europe is produced by EBD Group, the leading partner firm for the global biotech industry, with the support of the Biotechnology Innovation Organization (BIO).
Contact:
Katie Morales
Account’s manager
[email protected]
SOURCE Standard
